Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- CheckyesterdayChange DetectedPadova, Italy, 35128 has been added to the locations and Padua, Italy, 35128 has been removed.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedRevision notes show the page updated to version 3.5.0 (2026-03-16) with related changes, and the earlier version 3.4.3 (2026-02-12) removed.SummaryDifference0.1%

- Check23 days agoChange DetectedThe study record metadata has been updated with a new revision (v3.4.3) and added/adjusted dates (e.g., 2027-06-30 completion, 2026-02-12 QC date), with some older metadata dates removed.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision v3.4.2 was added and revision v3.4.1 was removed.SummaryDifference0.0%

- Check59 days agoChange DetectedPosted results data for the PALOMA-3 study, including Ctrough and AUC Day 1-15 PK endpoints for Cycle 2 Day 1 and Cycle 4 Day 1, with regional notes and timing details. Deleted several earlier results metrics definitions that were previously shown.SummaryDifference2%

- Check73 days agoChange DetectedThe changes update and standardize metadata display (glossary toggle, last update fields, FEAR Act labeling, and revision version) with some capitalization adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.